Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China
CK Li ( 李志光 ) FHKAM(Paed)
KW Chik ( 戚其威 ) FHKAM(Paed)
MMK Shing ( 成明光 ) FHKAM(Paed)
PMP Yuen ( 阮文賓 ) FHKAM(Paed)
Department of Paediatrics, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
GCF Chan ( 陳志峰 ) FHKAM(Paed)
SY Ha ( 夏修賢 ) FHKAM(Paed)
YL Lau ( 劉宇隆 ) FHKAM(Paed)
Department of Paediatrics, Tuen Mun Hospital, Tuen Mun, N.T., Hong Kong, China
ACW Lee ( 李志偉 ) FHKAM(Paed)
Department of Paediatrics, Caritas Medical Centre, 111 Wing Hong Street, Sham Shui Po, Kowloon, Hong Kong, China
CY Lee ( 李靜賢 ) FHKAM(Paed)
Department of Paediatrics, Princess Margaret Hospital, Lai Chi Kok, Kowloon, Hong Kong, China
CK Li ( 李志強 ) FHKAM(Paed)
SC Ling ( 凌紹祥 ) FHKAM(Paed)
Department of Paediatrics, Queen Elizabeth Hospital, Kowloon, Hong Kong, China
CW Luk ( 陸頌榮 ) FHKAM(Paed)
HL Yuen ( 袁煦樑 ) FHKAM(Paed)
Correspondence to: Dr CK Li
For the Hong Kong Paediatric Haematology and Oncology Group.
Received July 15, 2000
The Hong Kong Paediatric Haematology and Oncology Study Group conducted clinical studies on treatment of various paediatric cancers in Hong Kong. This article reported the treatment result of the various cancers presented in the annual workshop in February 2000. The five-year overall survival and event free survival were 80.2% and 62% for Acute Lymphoblastic Leukaemia, and were 60% and 53% for Acute Myeloid Leukaemia respectively. The other cancers with shorter follow up had three years overall and event free survival as follow: 75% and 62% for Medulloblastoma, 74% and 67% for Non-Hodgkin Lymphoma, 100% and 91% for extracranial Germ Cell Tumour, 30% and 20% for advanced neuroblastoma, 68% and 52% for Ewing's Sarcoma, 87% and 79% for Wilms' Tumour, 82% and 80% for Osteosarcoma, 56% and 45% for Rhabdomyosarcoma, and 60% and 50% for Hepatoblastoma respectively. The protocols had a high rate of adoption by the various hospitals, over 95% eligible patients were treated according to protocols. The toxicity of these protocols was acceptable with treatment related mortality less than 5% in most protocols.
